Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
Diagnosis and treatment of chronic lymphocytic leukemia: a review
M Shadman - Jama, 2023 - jamanetwork.com
Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …
Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities
AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - evidence.nejm.org
Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …
venetoclax in older patients and/or those with comorbidities with previously untreated …
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized …
WG Wierda, JN Allan, T Siddiqi, TJ Kipps… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic …
Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …
Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
PURPOSE The CLL14 study has established one-year fixed-duration treatment of
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic …
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic …
NCCN guidelines® insights: Chronic Lymphocytic leukemia/small Lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
BCL2 and MCL1 inhibitors for hematologic malignancies
BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …
hematologic cancers and play important roles in their biology either through dysregulation or …